Merck Powering Up In Emerging Markets Through Alliance And Pricing Strategies
This article was originally published in The Pink Sheet Daily
To rapidly ramp up business and increase sales in emerging markets from the current 18% to 25% in 2013, Merck is relying on an execution strategy that focuses on the combination of offering the right product with flexible pricing and stronger marketing.
You may also be interested in...
In a widely anticipated move, Merck has named current president Ken Frazier as CEO
SAN FRANCISCO - Western companies expanding in emerging markets are likely to distinguish themselves from competitors by successful execution and understanding of local markets, more so than by broad strategic differences, according to participants on a panel on Big Pharma perspectives on emerging markets at Elsevier Business Intelligence's PharmAsia Summit, held Oct. 26 in San Francisco
Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)
During the recent Pharmaceutical Strategic Alliances Conference in New York, Pfizer's Emerging Markets Business Unit President Jean-Michel Halfon and Merck's Chief Strategy Officer and Emerging Markets R&D Senior VP Merv Turner discussed priorities in tackling emerging markets. In part one, the execs outlined the steps companies should take to set up operations in emerging markets and in this second part they share their experiences in building a presence in China.